<DOC>
	<DOC>NCT00300027</DOC>
	<brief_summary>The purpose of this study is to define the recommended dose of BMS-582664 that could be safely combined with 5-fluorouracil, leucovorin, and irinotecan (FOLFIRI) or 5-fluorouracil, leucovorin, and oxaliplatin (FOLFOX) chemotherapy regimens in patients with advanced gastrointestinal malignancies and to evaluate the safety profile, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of these combinations.</brief_summary>
	<brief_title>Study of BMS-582664 in Combination With Either FOLFIRI or FOLFOX for Gastrointestinal (GI) Malignancies</brief_title>
	<detailed_description />
	<mesh_term>Gastrointestinal Neoplasms</mesh_term>
	<mesh_term>Digestive System Neoplasms</mesh_term>
	<criteria>Good performance status Advanced colorectal, pancreatic, esophageal or gastric cancer Tissue for analyses Adequate bone marrow, hepatic, renal function 46 weeks since prior therapy Adequate protection for women of child bearing potential (WOCBP) Brain metastasis Thromboembolic disease Cardiovascular disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2007</verification_date>
	<keyword>Advanced Gastrointestinal Malignancies</keyword>
</DOC>